
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Click the title above for a link to open the Pharmaceutical Executive October 2024 issue in an interactive PDF format.
about 2 years ago
Assembly Required: Building Blocks in Biopharmaabout 2 years ago
Pharma’s Cold Calling: CGT Space at a Critical Crossroadsabout 2 years ago
‘Selling a Vision’: Today’s Playbook for Startupsabout 2 years ago
Rafaat Rahmani: Beating the Oddsabout 2 years ago
AI: A Value Advantage? Maximizing Your Brand Outreachabout 2 years ago
How to Rally a Team Around Building a New Businessabout 2 years ago
Trading Quality for Convenience? The New Tech Balancing Actabout 2 years ago
Amazon Targeting the Transactional in the Pharma Market





